| Literature DB >> 18318898 |
Andreas W Henkel1, Wolfgang Sperling1, Andrea Rotter1, Udo Reulbach1, Cornelia Reichardt1, Dominikus Bönsch1, Juan M Maler1, Johannes Kornhuber1, Jens Wiltfang1.
Abstract
BACKGROUND: Different classes of antidepressant drugs are used as a treatment for depression by activating the catecholinergic system. In addition, depression has been associated with decrease of growth factors, which causes insufficient axonal sprouting and reduced neuronal damage repair. In this study, antidepressant treatments are analyzed in a cell culture system, to study the modulation of growth factors.Entities:
Mesh:
Substances:
Year: 2008 PMID: 18318898 PMCID: PMC2275236 DOI: 10.1186/1471-2210-8-6
Source DB: PubMed Journal: BMC Pharmacol ISSN: 1471-2210
Figure 1Differentiation by PMA and treatment with anti-depressive drugs alter cell morphology. A. Undifferentiated SY5Y cells; B. 10 days treatment with PMA; C. 14 days treatment with PMA and fluoxetine; D. 14 days treatment with PMA and tranylcypromine. Scale bar = 20 μm.
Figure 2Transcription of growth factors in SY5Y cells. A. Quantification of mRNA in PMA-treated SY5Y cells. Bar legend refers to all panels in figure 2; B. magnification of low abundant factors in panel A.; C. Modulation of transcription by amitriptyline; D. by fluoxetine; E. by tranylcypromine; F. by reboxetine. Values below 1 indicate antidepressant dependent reduction of growth factors.
Statistical significance analysis
| NGF | NT-3 | ||||||
| Amitryptiline | < 0.0001 | n.s. | n.s. | Amitryptiline | < 0.0001 | n.s. | 0.0001 |
| Fluoxetine | < 0.0001 | n.s. | n.s. | Fluoxetine | < 0.0001 | n.s. | 0.0017 |
| Tranylcypromine | 0.0014 | n.s. | 0.0032 | Tranylcypromine | < 0.0001 | n.s. | 0.0002 |
| Reboxetine | < 0.0001 | n.s. | n.s. | Reboxetine | 0.0004 | 0.0027 | 0.0001 |
| bFGF | Leptin | ||||||
| Amitryptiline | 0.0012 | n.s. | < 0.0001 | Amitryptiline | < 0.0001 | < 0.0001 | 0.0003 |
| Fluoxetine | < 0.0001 | n.s. | < 0.0001 | Fluoxetine | n.s. | < 0.0001 | < 0.0001 |
| Tranylcypromine | 0.004 | < 0.0001 | n.s. | Tranylcypromine | n.s. | < 0.0001 | < 0.0001 |
| Reboxetine | < 0.0001 | n.s. | < 0.0001 | Reboxetine | n.s. | 0.0021 | < 0.0001 |
| CNTF | CREB | ||||||
| Amitryptiline | n.s. | 0.0003 | < 0.0001 | Amitryptiline | n.s. | < 0.0001 | n.s. |
| Fluoxetine | 0.001 | < 0.0001 | < 0.0001 | Fluoxetine | n.s. | n.s. | n.s. |
| Tranylcypromine | 0.002 | < 0.0001 | < 0.0001 | Tranylcypromine | 0.0001 | < 0.0001 | n.s. |
| Reboxetine | n.s. | < 0.0001 | < 0.0001 | Reboxetine | < 0.0001 | < 0.0001 | 0.0002 |
| GDNF | -- | BDNF | |||||
| Amitryptiline | 0.001 | < 0.0001 | 0.005 | Amitryptiline | n.s. | n.s. | 0.002 |
| Fluoxetine | < 0.0001 | < 0.0001 | 0.0003 | Fluoxetine | 0.0005 | 0.0012 | n.s. |
| Tranylcypromine | < 0.0001 | n.s. | 0.0009 | Tranylcypromine | n.s. | 0.0007 | n.s. |
| Reboxetine | n.s. | n.s. | 0.0006 | Reboxetine | < 0.0001 | n.s. | 0.0017 |
Expressions of growth factors were tested with Student's t-test against the corresponding expression levels at the start of the experiments. Expression levels of controls, which were treated for 10 days with PMA, were normalized before testing. The values in the table represent the p-values, obtained by the t-test. The significance level was set at α = 0.004.
Figure 3Effects of rTMS. Transcription of growth factors after rTMS in A. PC-12 cells and in B. SY5Y cells. mRNA levels of untreated control cells are set to 1.